A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Required: CD19 expression

Must have received: systemic therapy — CLL/SLL, Cohort 1A and 1C: at least 2 prior lines; Cohort 1B: at least 1 prior line and is BTKi-sensitive; MCL, Cohort 2A and 2C: relapse or progressed after 2 or more lines including BTKi; Large B-cell lymphoma/B-NHL: at least 1 prior line

Cohort 1A and 1C: at least 2 prior lines of systemic therapy for CLL/SLL. Cohort 1B: at least 1 prior line of therapy and is bruton tyrosine kinase inhibitor (BTKi)-sensitive. Cohort 2A and 2C: Relapse or progressed after 2 or more lines of therapy including BTKi. R/R B-NHL after at least 1 prior line of therapy.

Cannot have received: CAR T-cell therapy

Exception: within 12 weeks

Prior CAR T-cell therapy or autologous-haematopoietic stem cell transplant (HSCT) within 12 weeks

Cannot have received: autologous-haematopoietic stem cell transplant

Exception: within 12 weeks

Prior CAR T-cell therapy or autologous-haematopoietic stem cell transplant (HSCT) within 12 weeks

Cannot have received: T-cell engager

Exception: within 8 weeks

prior T-cell engager (TCE) within 8 weeks

Cannot have received: allogeneic HSCT

Exception: within 24 weeks

Prior allogeneic HSCT or solid organ transplantation within 24 weeks of starting Cycle 1 Day 1

Cannot have received: solid organ transplantation

Exception: within 24 weeks

Prior allogeneic HSCT or solid organ transplantation within 24 weeks of starting Cycle 1 Day 1

Cannot have received: radiation therapy

Exception: within 28 days

Radiation therapy within 28 days

Cannot have received: anticancer therapy

Exception: within 5 half-lives or 21 days (whichever is shorter)

Any anticancer therapy within 5 half-lives or 21 days (whichever is shorter) prior to treatment